Quarterly report · Q2
2372.TEDINET S100PFYJ
Period2022-04-01 → 2022-09-30
Filed2022-11-04
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥15.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥858m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥994m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥723m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥721m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥30.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥22.7bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥18.5bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥16.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥12.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥10.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.0bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.0bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.0bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥653m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥740m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥164.17 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.8 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥162.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.99 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.5 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥163.91 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥162.17 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥59.85 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 39.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.4% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥68m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥28m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥39m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥118m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥673m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥619m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥618m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥181m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥88m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥82m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥953m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥503m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥449m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥24m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥61m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥601m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥641m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥32m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥8m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥23m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | −¥100m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥492m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥492m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥658m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥294m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥291m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥311m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥29m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥240m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥856m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥497m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥359m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥123m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥77m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.6bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥7.3bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥6.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥468m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥7.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥6.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥492m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 548
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 4779450 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.3947 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 841900 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0695 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 825000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0681 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 226900 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0187 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 160956 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0133 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 138223 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0114 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 115400 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0095 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 105734 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0087 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 101800 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0084 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 96600 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0080 | |
| Number of shares held | CurrentQuarterInstant | 7391963 | |
| Shareholding ratio | CurrentQuarterInstant | 0.6105 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 230600 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 11949800 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 119498 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 157965 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 12338365 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 119498 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 230600 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 230600 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0187 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 230600 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 230600 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0187 | |
| Cash and deposits | Prior1YearInstant | 6400000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 6983000000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 2846000000 | JPY |
| Accounts receivable trade | CurrentQuarterInstant | 3264000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 277000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 388000000 | JPY |
| Real estate for sale | Prior1YearInstant | 1535000000 | JPY |
| Real estate for sale | CurrentQuarterInstant | 1539000000 | JPY |
| Work in process | Prior1YearInstant | 502000000 | JPY |
| Work in process | CurrentQuarterInstant | 366000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |